176 related articles for article (PubMed ID: 28375712)
21. Differential gene expression in ovarian carcinoma: identification of potential biomarkers.
Hibbs K; Skubitz KM; Pambuccian SE; Casey RC; Burleson KM; Oegema TR; Thiele JJ; Grindle SM; Bliss RL; Skubitz AP
Am J Pathol; 2004 Aug; 165(2):397-414. PubMed ID: 15277215
[TBL] [Abstract][Full Text] [Related]
22. Novel Genomic Biomarker Candidates for Cervical Cancer As Identified by Differential Co-Expression Network Analysis.
Kori M; Gov E; Arga KY
OMICS; 2019 May; 23(5):261-273. PubMed ID: 31038390
[TBL] [Abstract][Full Text] [Related]
23. The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression.
Liu Y; Zong ZH; Guan X; Wang LL; Zhao Y
Gene; 2017 Oct; 633():42-47. PubMed ID: 28864116
[TBL] [Abstract][Full Text] [Related]
24. Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells.
Sun P; Sehouli J; Denkert C; Mustea A; Könsgen D; Koch I; Wei L; Lichtenegger W
J Mol Med (Berl); 2005 Jun; 83(6):457-67. PubMed ID: 15770498
[TBL] [Abstract][Full Text] [Related]
25. Observation of significant biomarkers in osteosarcoma via integrating module- identification method with attract.
Qi J; Ma L; Wang X; Li Y; Wang K
Cancer Biomark; 2017 Jul; 20(1):87-93. PubMed ID: 28759958
[TBL] [Abstract][Full Text] [Related]
26. Coordinately up-regulated genes in ovarian cancer.
Hough CD; Cho KR; Zonderman AB; Schwartz DR; Morin PJ
Cancer Res; 2001 May; 61(10):3869-76. PubMed ID: 11358798
[TBL] [Abstract][Full Text] [Related]
27. Dysregulation of mitotic machinery genes precedes genome instability during spontaneous pre-malignant transformation of mouse ovarian surface epithelial cells.
Urzúa U; Ampuero S; Roby KF; Owens GA; Munroe DJ
BMC Genomics; 2016 Oct; 17(Suppl 8):728. PubMed ID: 27801298
[TBL] [Abstract][Full Text] [Related]
28. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
29. Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer.
Bapat SA; Krishnan A; Ghanate AD; Kusumbe AP; Kalra RS
Cancer Res; 2010 Jun; 70(12):4809-19. PubMed ID: 20530682
[TBL] [Abstract][Full Text] [Related]
30. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data.
Zhang C; Peng L; Zhang Y; Liu Z; Li W; Chen S; Li G
Med Oncol; 2017 Jun; 34(6):101. PubMed ID: 28432618
[TBL] [Abstract][Full Text] [Related]
31. Characterizing biomarkers in osteosarcoma metastasis based on an ego-network.
Liu Z; Song Y
Biotechnol Lett; 2017 Jun; 39(6):841-848. PubMed ID: 28229297
[TBL] [Abstract][Full Text] [Related]
32. Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining.
Li H; Li J; Gao W; Zhen C; Feng L
J Ovarian Res; 2020 Mar; 13(1):27. PubMed ID: 32160916
[TBL] [Abstract][Full Text] [Related]
33. A network-pathway based module identification for predicting the prognosis of ovarian cancer patients.
Wang X; Wang SS; Zhou L; Yu L; Zhang LM
J Ovarian Res; 2016 Nov; 9(1):73. PubMed ID: 27806724
[TBL] [Abstract][Full Text] [Related]
34. Differential network analysis reveals the genome-wide landscape of estrogen receptor modulation in hormonal cancers.
Hsiao TH; Chiu YC; Hsu PY; Lu TP; Lai LC; Tsai MH; Huang TH; Chuang EY; Chen Y
Sci Rep; 2016 Mar; 6():23035. PubMed ID: 26972162
[TBL] [Abstract][Full Text] [Related]
35. Predicting of disease genes for gestational diabetes mellitus based on network and functional consistency.
Zhang Q; He M; Wang J; Liu S; Cheng H; Cheng Y
Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():91-6. PubMed ID: 25666344
[TBL] [Abstract][Full Text] [Related]
36. An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data.
Sugaya N; Ikeda K; Tashiro T; Takeda S; Otomo J; Ishida Y; Shiratori A; Toyoda A; Noguchi H; Takeda T; Kuhara S; Sakaki Y; Iwayanagi T
BMC Pharmacol; 2007 Aug; 7():10. PubMed ID: 17705877
[TBL] [Abstract][Full Text] [Related]
37. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
38. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
Tang W; Ren A; Xiao H; Sun H; Li B
Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
[TBL] [Abstract][Full Text] [Related]
39. Construction of an immunorelated protein-protein interaction network for clarifying the mechanism of burn.
Gao Y; Nai W; Yang L; Lu Z; Shi P; Jin H; Wen H; Wang G
Burns; 2016 Mar; 42(2):405-13. PubMed ID: 26739088
[TBL] [Abstract][Full Text] [Related]
40. A 19-Gene Signature of Serous Ovarian Cancer Identified by Machine Learning and Systems Biology: Prospects for Diagnostics and Personalized Medicine.
Kori M; Demirtas TY; Comertpay B; Arga KY; Sinha R; Gov E
OMICS; 2024 Feb; 28(2):90-101. PubMed ID: 38320250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
